NO20055888L - Kombinasjonsterapi - Google Patents

Kombinasjonsterapi

Info

Publication number
NO20055888L
NO20055888L NO20055888A NO20055888A NO20055888L NO 20055888 L NO20055888 L NO 20055888L NO 20055888 A NO20055888 A NO 20055888A NO 20055888 A NO20055888 A NO 20055888A NO 20055888 L NO20055888 L NO 20055888L
Authority
NO
Norway
Prior art keywords
cpt
combination
administration
vascular
warm
Prior art date
Application number
NO20055888A
Other languages
English (en)
Norwegian (no)
Inventor
Anderson Joseph Ryan
Original Assignee
Angiogene Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0314097A external-priority patent/GB0314097D0/en
Priority claimed from GB0316181A external-priority patent/GB0316181D0/en
Application filed by Angiogene Pharm Ltd filed Critical Angiogene Pharm Ltd
Publication of NO20055888L publication Critical patent/NO20055888L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20055888A 2003-06-18 2005-12-12 Kombinasjonsterapi NO20055888L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0314097A GB0314097D0 (en) 2003-06-18 2003-06-18 Combination therapy
GB0316181A GB0316181D0 (en) 2003-07-10 2003-07-10 Combination therapy
PCT/GB2004/002624 WO2004112801A2 (en) 2003-06-18 2004-06-18 Compositions comprising zd6126 together with 5-fu, cpt-11 or 5-fu and cpt-11 having vascular damaging activity for treating e.g. colorectal cancer

Publications (1)

Publication Number Publication Date
NO20055888L true NO20055888L (no) 2006-03-16

Family

ID=33542667

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055888A NO20055888L (no) 2003-06-18 2005-12-12 Kombinasjonsterapi

Country Status (11)

Country Link
US (1) US20060142239A1 (ko)
EP (1) EP1658084A2 (ko)
JP (1) JP2006527753A (ko)
KR (1) KR20060036058A (ko)
AU (1) AU2004248968A1 (ko)
BR (1) BRPI0411567A (ko)
CA (1) CA2529409A1 (ko)
IL (1) IL172560A0 (ko)
MX (1) MXPA05013827A (ko)
NO (1) NO20055888L (ko)
WO (1) WO2004112801A2 (ko)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005117980A1 (en) * 2004-06-04 2005-12-15 Pfizer Products Inc. Method for treating abnormal cell growth
US20090118340A1 (en) * 2007-10-12 2009-05-07 Jerzy Gebicki Method for inhibiting and/or preventing formation of cancer metastases and seconddary malignant cancers
WO2024063569A1 (ko) * 2022-09-22 2024-03-28 (의) 삼성의료재단 종양 혈관 파괴용 약학 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4864021A (en) * 1984-10-30 1989-09-05 Otsuka Pharmaceutical Co., Ltd. 5-fluorouracil derivatives
GB9714249D0 (en) * 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
WO2001074369A1 (en) * 2000-03-31 2001-10-11 Angiogene Pharmaceuticals Ltd. Divided dose therapies with vascular damaging activity
EE200200565A (et) * 2000-03-31 2004-06-15 Angiogene Pharmaceuticals Ltd. Vaskulaarse kahjustava toimega kombinatsioonravi
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
US6720323B2 (en) * 2000-07-07 2004-04-13 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
AU6623301A (en) * 2000-07-07 2002-01-21 Angiogene Pharm Ltd Colchinol derivatives as vascular damaging agents
CA2482591A1 (en) * 2002-04-16 2003-10-30 Astrazeneca Ab Combination therapy for the treatment of cancer

Also Published As

Publication number Publication date
WO2004112801A2 (en) 2004-12-29
IL172560A0 (en) 2006-04-10
JP2006527753A (ja) 2006-12-07
AU2004248968A1 (en) 2004-12-29
WO2004112801A3 (en) 2005-03-24
US20060142239A1 (en) 2006-06-29
MXPA05013827A (es) 2006-03-13
KR20060036058A (ko) 2006-04-27
BRPI0411567A (pt) 2006-08-01
EP1658084A2 (en) 2006-05-24
CA2529409A1 (en) 2004-12-29

Similar Documents

Publication Publication Date Title
NO20071426L (no) Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib
NO20050807L (no) Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser
DK1551409T3 (da) Anvendelse af quinazolinderivatet ZD6474 kombineret med gemcitabin og eventuelt ioniserende stråling ved behandling af cancer
TR200003879T2 (tr) İn vivo ışın tedavisine duyarlılaştırıcı özelliklere sahip farnesil protein transferaz inhibitörleri@
NO20050528L (no) Kombinasjon av VEGF reseptor tyrosin kinase inhibitorer for behandling av kreft
HK1071310A1 (en) Combination therapy for the treatment of cancer
BRPI0418351A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, métodos de limitar a proliferação celular em um humano ou animal, de tratamento de um humano ou animal sofrendo de cáncer, de tratamento de profilaxia de cáncer, de tratamento de um humano ou animal sofrendo de uma doença neoplásica, de tratamento de um humano ou animal sofrendo de uma doença prolifetativa de tratamento de cáncer, para o tratamento de infecções associadas com cáncer, para o tratamento profilático de infecções associadas com cáncer, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, método de inibir a chk1 quinase, e, processo para a preparação de um composto ou um sal farmaceuticamente aceitável do mesmo
NO20071428L (no) Kombinasjon inneholdende ZD6474 og Imatinib
CY1105803T1 (el) Συνθεση πepιλαμβανουσα καμπτοθεκινη και ενα παραγωγο πυριμιδινης για τη θepαπεια καρκινου
IS6558A (is) Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni
PT1017675E (pt) Derivados da camtotecina altamente lipofilos
CY1111565T1 (el) Θεραπεια συνδυασμου του zd6474 με 5-fu και/ή cpt-11
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
ATE396986T1 (de) Pyrimidylpyrrolderivate, die als kinaseinhibitoren wirken
DE60313754D1 (de) Botanischer extrakt mit antikrebs-aktivität enthaltend isoliquiritigenin
BRPI0413410A (pt) co-administração de um polissacarìdeo com um agente quimioterapêutico para o tratamento de cáncer
NO20064753L (no) Kombinasjonsterapi
ATE290388T1 (de) Kombination von selen-haltigen verbindungen mit gemcitabin oder mitomycin c
NO20055888L (no) Kombinasjonsterapi
BR0309996A (pt) Composto, composição farmacêutica, método de tratar ou melhorar doenças ou condições proliferativas, uso de um composto, e, método de tratar ou melhorar doenças inflamatórias
NO20076657L (no) Kombinasjonsterapi av cancer med AZD2171 og gemcitabin
HK1074840A1 (en) Novel dithiolopyrrolones with therapeutic activity
HUP0302629A2 (hu) Camptotechin és sztilbénszármazékok kombinációját tartalmazó gyógyszerkészítmények rák kezelésére
NO20075508L (no) Stannsoporfinpreparater og administrering
TW200500073A (en) Pharmaceutical composition comprising an indolopyrrolocarbazole derivative and use thereof

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application